ReviewResearch and practice in thrombosis and haemostasis2026
Toward improved thrombolysis in ischemic stroke: targeting nonfibrin components.
Review in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanomedicine beyond carriers - devices, cells & living therapeutics.Biomedical microdevices · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A State of the Art lecture titled "Targeting nonfibrin components in ischemic stroke" was presented at the International Society on Thrombosis and Haemostasis Congress in 2025. Fibrinolysis using recombinant tissue plasminogen activators remains the primary pharmacologic approach for reperfusion therapy in ischemic stroke. Its clinical benefit has been well established over the past 3 decades. However, fibrinolytic therapy is not universally effective, and its limitations have become increasingly apparent. Recent research has provided deeper insights into acute ischemic stroke thrombus composition and architecture, revealing complex structures containing not only fibrin but also cellular and extracellular components that contribute to fibrinolysis resistance. These findings have led to the development of novel strategies aimed at targeting nonfibrin components to enhance overall thrombolysis and overcome fibrinolysis resistance. This review highlighted the current evidence from studies on ischemic stroke thrombi that underpin emerging thrombolytic strategies that target nonfibrin components and discusses their potential clinical implications. Finally, relevant new data on this topic presented during the 2025 International Society on Thrombosis and Haemostasis Congress were summarized.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.